Sign in
Taking people in South KoreaPhase 2

Tests two chemotherapy schedules for older adults with mantle cell lymphoma

Compares alternating rituximab, bendamustine and cytarabine with standard rituximab-bendamustine in older mantle cell lymphoma patients.

Key facts

Who runs it
Kim, Seok Jin
Where
Seoul, South KoreaSee the site
Trial code
Registry title
A Study Comparing Rituximab/Bendamustin(RB) Alternating With Rituximab/Bendamustin/Cytarabin(RBAC) With RB Therapy in Elderly Patients With Mentle Cell Lymphoma
Status
Recruiting
Phase
Phase 2
People taking part
90 people, planned
Started
18 Oct 2022
Expected to end
31 Dec 2029
Type of study
Interventional, 2 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • RB/RBAC alternating
  • RB
Record updated
23 April 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for older adults with newly diagnosed mantle cell lymphoma who have not been treated before and cannot have a stem cell transplant.

Age
70 years or older, or 60 to 69 years if a high-dose therapy with autologous stem cell transplant is not possible.
Sex
All sexes can join.
Disease stage
Newly diagnosed mantle cell lymphoma that is CD20 positive and confirmed by biopsy. Ann Arbor stage 1 disease and in-situ mantle cell lymphoma cannot join.
Earlier treatment
No earlier treatment for this lymphoma. No treatment for Hodgkin or non-Hodgkin lymphoma within the last 5 years.
Biomarker or test result
The lymphoma must be CD20 positive.

Main reasons for not taking part

  • Lymphoma in the brain or spinal cord area (central nervous system involvement)
  • Another active cancer within the past 3 years, apart from a few treated localized types
  • Known HIV infection
  • Serious unstable illness, such as heart failure NYHA class 3 or higher, a heart attack or angina within 6 months, or an uncontrolled infection
  • Allergy to bendamustine, rituximab, cytarabine or mannitol

The registry criteria, word for word

Show all 18 criteriaShow less

Who can take part

  • newly diagnosed, previously untreated, histologically confirmed CD20+ mantle cell lymphoma, confirmed by WHO classification criteria
  • age ≥70 years or 60-69 years if the patients are ineligible for high-dose therapy with autologous stem cell transplantation
  • ECOG performance status 2 or less
  • Adequate organ functions; adequate heart function: LVEF ≥50% by echocardiography or MUGA; adequate renal function: serum creatinine ≤ 2.0mg/dL or CrCl ≥40 mL/min based on the Cockcroft-Gault method; adequate hepatic function: ≤2.5 times the upper limit of ALT (≤5 times the upper limit of ALT if the elevation is attributed by underlying lymphoma) and ≤2 times the upper limit of ALT (≤3 times the upper limit of total bilirubin if the elevation is attributed by underlying lymphoma); adequate hematologic function: absolute neutrophil counts (ANC) ≥ 1,500/mL, platelet counts ≥ 100,000/mL (any ANC and platelet counts are allowed, if they were related to bone marrow involvement)
  • Written informed consent

Who cannot take part

  • Prior treatment for Hodgkin lymphoma or non-Hodgkin lymphoma within the last 5 years
  • HBsAg (+) or anti-HBc Ab (+) (patients will be eligible if they receive appropriate prophylactic antiviral therapy using entecavir, tenofovir, and so on)
  • History of prior hepatitis C infection (patients positive for HCV IgG will be eligible if they are negative for HCV-RNA)
  • concomitant administration of any other experimental drugs under investigation
  • major surgical procedure or significant trauma within 28 days before start of study treatment, open biopsy within 7 days before start of study treatment
  • Ann Arbor stage 1 disease
  • Active malignancy within the past 3 years except for localized non-melanoma skin cancer, papillary thyroid cancer, cervical carcinoma in situ, breast cancer in situ, or localized prostate cancer that has been definitely treated,
  • Known history of human immunodeficiency virus (HIV) infection
  • any serious illness or medical conditions that are unstable or could jeopardize the safety of the patient and his/her compliance in the study; Congestive heart failure ≥ NYHA class 3; Acute coronary syndrome within 6 months (unstable angina or new-onset angina, myocardial infarct, or ventricular arrhythmia); History of significant neurological or psychological disorder including dementia and seizure disorder; Severe chronic obstructive pulmonary disease with hypoxemia; Cerebrovascular disease including transient ischemic attack within the past 6 months; Non-healing wound, ulcer, or bone fracture; Active uncontrolled bacterial, viral, or fungal infection requiring systemic therapy
  • Known hypersensitivity to bendamustine, rituximab, cytarabine, or mannitol
  • In-situ mantle cell lymphoma
  • Central nervous system involvement
  • If the patient's partner is a woman who could possibly get pregnant, men who didn't have a vasectomy must agree to use medically recommended methods for adequate contraception (tubal ligation, intrauterine devices, or barriers [diaphragm, cervical cap] in the patient's partner and the use of condoms in men) when sexually active

Where in South Korea

  • Samsung Medical CenterSeoul, South KoreaContact: Seok Jin Kim, Ph.DTaking people

About the trial

What the trial wants to find out

This is a phase 2, multicenter, open-label, active-controlled randomized trial to determine efficacy and safety of rituximab/bendamustine (RB) alternating with rituximab/bendamustine/cytarabine (RBAC) compared with standard RB alone in the first-line treatment of elderly patients with mantle cell lymphoma, who are not eligible for high-dose therapy followed by autologous stem cell transplantation.

The 2 groups in the trial

  • RB/RBAC alternatingTreatment being tested

    Every 4 weeks for 6 cycles RB (1st, 3rd, and 5th cycles) * Rituximab + Bendamustine RBAC (2nd, 4th, and 6th cycles) * Rituximab + Bendamustine + Cytarabine

  • RBExisting treatment, for comparison

    Every 4 weeks for 6 cycles \- Rituximab + Bendamustine

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A Randomized Phase II Trial Comparing Rituximab/Bendamustine(RB) Alternating With Rituximab/Bendamustine/Cytarabine(RBAC) With RB as Induction Therapy in Elderly Patients With Newly Diagnosed and Transplant-ineligible Mantle Cell Lymphoma
Plain-language title
Tests two chemotherapy schedules for older adults with mantle cell lymphomaGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Record updated
23 April 2026